INmune Bio Partners With Cell And Gene Therapy Catapult To Establish Large-Scale, Commercial-Ready Manufacturing For Cell Therapy Platforms

Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ:INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK.

INmune Bio's therapies harness the innate immune system, the body's first line of defense, to treat diseases including Alzheimer's, prostate cancer, and recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. With active trials across the UK, Europe, Australia, Canada and the US, the company is advancing a diversified portfolio addressing significant unmet medical needs.

The collaboration builds on INmune Bio's existing manufacturing base at the Royal Free Hospital and leverages CGT Catapult's expertise at its Stevenage Manufacturing Innovation Centre. The initial focus is on scaling production of CORDStromTM, a promising therapy for RDEB. In a recent Phase 2 randomized trial, CORDStromTM reduced pain and itch while showing potential to improve skin integrity and disease activity. INmune Bio estimates that approximately 4,000 children with intermediate to severe RDEB in the US, UK and EU could benefit, positioning CORDStromTM for clinical trial supply and eventual Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions.  The Company believes that CORDStrom™ could be the first cell therapy to address the systemic nature of RDEB.

Following CORDStromTM, INmune Bio plans to transition production of INKmune®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and UK, including the Phase 2 study in metastatic castration-resistant prostate cancer.

This partnership with CGT Catapult accelerates the Company's path to commercialization by delivering efficient, scalable manufacturing while preserving operational control.